Увійти

Готові списки джерел за темами / Theophylline

Добірка наукової літератури з теми "Theophylline"

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 7 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Theophylline".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Статті в журналах з теми "Theophylline":

1

Tatsis, G., J. Danos, M. Gaga, D. Pantelakis, M. Veslemes, and J. Jordanoglou. "A Single-Blind Crossover Study of Two Different Slow Release Theophylline Preparations." Journal of International Medical Research 16, no. 6 (November 1988): 452–58. http://dx.doi.org/10.1177/030006058801600607.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

In a single-blind crossover study, two slow release theophylline preparations were evaluated in 18 patients with chronic bronchitis or asthma without cardiac, renal or liver disease. After randomization into two groups, patients were treated, in a crossover study design, with 600 mg choline theophyllinate or 300 mg anhydrous theophylline administered orally every 12 h for 7 days. A 2-day washout period separated the two periods of treatment evaluation. Blood samples in which plasma theophylline concentration was to be measured were taken at 7.30 a.m., 2.00 p.m. and 7.30 p.m. during the last 5 days of therapy with each drug. The mean fluctuation in plasma theophylline concentration was ≤40% in all 18 patients taking choline theophyllinate yet in only 15 (83%) patients administered anhydrous theophylline. Salbutamol inhaler was more frequently required for the relief of bronchospasm when taking anhydrous theophylline than when taking choline theophyllinate (total of 41 vs 25 puffs, respectively, over 7 days). Drug-related adverse reactions occurred in four patients while taking anhydrous theophylline and in one patient while taking choline theophyllinate.

2

Boner, A. L., G. De Stefano, G. Vallone, M. Plebani, and P. Ventura. "Absolute and Relative Bioavailability of a Slow Release Theophylline Preparation in Asthmatic Children." Journal of International Medical Research 15, no. 5 (September 1987): 282–92. http://dx.doi.org/10.1177/030006058701500504.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This study was carried out on 14 asthmatic childen aged 7–13 years. They all received three preparations (aminophylline by intravenous infusion, lysine theophyllinate orally in solution and slow release theophylline orally as capsules) in a single dose of 100 mg active ingredient in a crossover design. Plasma theophylline concentrations, determined by a fluorescent polarization immunoassay, were evaluated both by compartmental and non-compartmental analysis. After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (± SD) 3.19 ± 0.63 μg/ml and 8.71 ± 2.30 h, respectively, compared to 4.51 ± 0.94 μg/ml and 1.96 ± 0.85 h, respectively, for the oral normal release solution. Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (± SD) 92.7 ± 23.2% and 83.14 ± 14.69%, respectively. These are similar to the values found with other slow release formulations in paediatric patients.

3

BRODWALL, ERLING K. "The Resorption of Theophyllamine (Theophylline Ethylenediamine)." Acta Medica Scandinavica 146, no. 2 (April 24, 2009): 123–26. http://dx.doi.org/10.1111/j.0954-6820.1953.tb10222.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Nolte, Matthias, Ingo Pantenburg, and Gerd Meyer. "Konkurrierende Liganden: Theophyllin als nicht- und stark koordinierender Ligand in Quecksilber(II)-Komplexen / Competing Ligands: Theophylline as Non- and Strongly Coordinating Ligand in Mercury(II) Complexes." Zeitschrift für Naturforschung B 61, no. 6 (June 1, 2006): 758–65. http://dx.doi.org/10.1515/znb-2006-0617.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

[{Hg(CF3)2}(ThpH)(H2O)](H2O) (1), [{Hg4(Thp)4}(ClO4)4(H2O)8](H2O)4 (2), [{Hg(ThpH)2} (NO3)](NO3) (3) and {Hg(Thp)Cl}(H2O) (4) (ThpH = theophylline, C7H8N4O2) have been synthesized by slow evaporation of aqueous solutions of the mercuric salts Hg(CF3)2, Hg(ClO4)2, Hg(NO3)2, or HgCl2 and theophylline. Their crystal structures were determined on the basis of single crystal X-ray data. The coordination polymers 1 and 2 crystallize with triclinic symmetry, P1̅ (no. 2), with a = 468.8(2), b = 1256.4(5), c = 1445.5(6) pm, α = 67.15(3), β = 89.21(3), γ = 89.40(3)° and a = 833.6(1), b = 1862.7(2), c = 2182.9(2) pm, α = 111.61(1), β = 90.98(1), γ = 95.51(1)°, respectively. 3 and 4 crystallize with monoclinic symmetry, Pc (no. 7), a =1194.1(1), b=1258.8(2), c=735.5(2) pm, β =96.96(2)° and P21/n (no. 14), a=1069.0(2), b =911.6(1), c=1089.9(2) pm and β = 96.87(2)°. In 1 the theophylline molecules are non-coordinating to mercury and leave the Hg(CF3)2 molecule unchanged. Only weak electrostatic attractions to one keto-oxygen atom of theophylline and one water molecule hold this co-crystallisate together. In 2, the theophyllinate anion, Thp−, strongly coordinates with both N(7) and N(9) to HgII forming a large ring with eight Hg atoms that incorporates the water molecules. One sort of nitrate ions in 3 is weakly attached to HgII with the theophylline molecules still bound strongly through N(9). The chloride ligand and the theophyllinate ion seem to have the same strengths as ligands in 4 as they are both attached to HgII with the shortest distances possible

5

Wang, L. C., S. F. Man, and A. N. Belcastro. "Metabolic and hormonal responses in theophylline-increased cold resistance in males." Journal of Applied Physiology 63, no. 2 (August 1, 1987): 589–96. http://dx.doi.org/10.1152/jappl.1987.63.2.589.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The effects of theophylline (a phosphodiesterase inhibitor-adenosine receptor antagonist) and substrate feeding (Ensure, 250 kcal/235 ml) on cold resistance were studied in seminude males undertaking submaximal (50% maximum O2 consumption), intermittent (34% of total time) exercise in the cold (-5 to 15 degrees C, individually adjusted) for 3 h. Each subject (n = 7) served as his own control and was tested on a weekly schedule. Under control treatment, rectal temperature (Tre) decreased by 0.9 degrees C to approximately 36.2 degrees C after cold exposure, whereas under theophylline and Ensure, the decrease of Tre was only 0.4 degrees C, indicating a significant increase (P less than 0.05) in cold resistance (50% better than control). The plasma concentration of theophylline was 4.8–5.9 micrograms/ml and was positively correlated with plasma concentration of free fatty acids. Plasma norepinephrine (NE) increased significantly during cold exposure; the absolute concentration was significantly higher after theophylline pretreatment. The plasma concentrations of glucose, epinephrine, cortisol, and adenosine 3′,5′-cyclic monophosphate did not change and the changes of free thyroxine and triiodothyronine were minor. Together, the effectiveness of theophylline + Ensure in acutely increasing cold resistance may be due to increased substrate availability for thermogenesis, part of which, through theophylline's potentiation of both sympathetic release of NE and NE-stimulated lipolysis and part of which, through supplementary feeding of Ensure.

6

Jeong, Chan Su, Soon Chul Hwang, Daniel W. Jones, Hwan Sun Ryu, Kieho Sohn, and Charles D. Sands. "Theophylline Disposition in Korean Patients with Congestive Heart Failure." Annals of Pharmacotherapy 28, no. 3 (March 1994): 396–401. http://dx.doi.org/10.1177/106002809402800319.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

OBJECTIVE: This study proposed to determine the systemic disposition on of theophyllinein Korean adult patients during decompensated congestive heart failure compared with disposition after recovery. DESIGN: An experimental, prospective, self-controlled, non randomized design was used. SETTING: The study was performed in a general communityhospital located in Pusan, Korea. PATIENTS: Eight nonsmoking elderly Korean patients with decompensated congestive heart failure presenting to the emergency department were included in the study. Consecutive patients who met entrance criteria were selected. All patients completed the study. INTERVENTIONS: A single dose of aminophylline 6 mg/kg was administered by intravenous infusion over 30 minutes. Standard methods of congestive heart failure therapy were used in each patient, including bed rest, restriction of sodium, and drug therapy including digoxin. After compensation of congestive heart failure was achieved the theophylline infusion was repeated. OUTCOME MEASURES: Serum theophylline concentrations were measured at 2, 6, 12, and 18 hours after completion of the dose at base line and following treatment. RESULTS: A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 ± 2.8 to 43.4 ± 4.7 mL/kg/h [mean ± SEM]; p<0.01). Comparison of these results with a computer model based on literature averages of peoples of all nationalities showed significant underprediction of theophylline clearance both before (p<0.05)and after (p<0.01) treatment. The theophylline elimination half-life prior to treatment was 18.2 ± 2.2 hours and decreased to 9.1 ± 0.8 hours following treatment(p<0.O1). There was no statistical difference between the computer-model predicted initial theophylline half-life and the measured value, but the model significantly underpredicted the improvement following treatment. CONCLUSIONS: The improvement in theophylline clearance demonstrated in this study appears to be greater than that reported for Western patients. This has practical application to the calculation of appropriate theophylline maintenance dosage regimens in Korean patients with cardiac failure. These data support the need for consideration of racial differences in individualizing dosage regimens. We suggest that all kinetic models, whether software supported or not, should consider incorporating ethnic origin as a demographic factor that helps select the proper model for individual patients.

7

Rees, Sharon. "THEOPHYLLINE." Journal of Prescribing Practice 3, no. 2 (February 2, 2021): 52. http://dx.doi.org/10.12968/jprp.2021.3.2.52.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

&NA;. "Theophylline." Reactions Weekly &NA;, no. 728 (November 1998): 12. http://dx.doi.org/10.2165/00128415-199807280-00041.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1167 (September 2007): 26. http://dx.doi.org/10.2165/00128415-200711670-00078.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1152 (May 2007): 25–26. http://dx.doi.org/10.2165/00128415-200711520-00078.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Theophylline":

1

Awosika, Ajoritsedere. "Biopharmacy of sustained-release theophylline." Thesis, University of Bradford, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.257819.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Purkiss, Ronald. "Bioequivalence of sustained release theophylline formulations." Thesis, Aston University, 1986. http://publications.aston.ac.uk/12472/.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The bioequivalence of sustained release theophylline formulations, marketed in the United Kingdom, has been investigated in relation to the co-administration of food in both single dose and steady state volunteer studies. The effect of food on pharmacokinetic parameters and their clinical relevance was researched. Experimentation using drug induced modification of gastric motility to ascertain the component influences of the rate of gastric emptying on the absorption of theophylline from sustained release formulations was conducted. Prolongation of time to maximum plasma theophylline concentration by food reported in the literature and its clinical importance was investigated in once daily compared with twice daily administration of sustained release theophylline formulations and smoking habit. The correlation between saliva and plasma theophylline concentrations as a means of developing a non-invasive sampling techniques was examined. Data obtained from in vitro dissolution studies was compared with in vivo results. This thesis has shown no significant differences occurred in the pharmacokinetic parameters measured between sustained release formulations available in the United Kingdom. The investigations into the influence of food on prolongation of time to maximum plasma theophylline concentration and other measured pharmacokinetic parameters demonstrated no important pharmacokinetic or clinical effects. Smoking adults taking sustained release theophylline formulations had similar drug clearances to those reported in the literature for smokers taking plain uncoated theophylline formulations.

3

Boer, Jason. "Mechanistic investigation of cytochrome P450 1A2 catalyzed metabolism of 8-alkylxanthines /." Thesis, Connect to this title online; UW restricted, 2003. http://hdl.handle.net/1773/8161.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Zhang, Shuo. "Physical properties and crystallization of theophylline co-crystals." Licentiate thesis, KTH, Transport Phenomena, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-13255.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This work focuses on the physical properties and crystallization of theophyline co-crystals. Co-crystals of theophylline with oxalic acid, glutaric acid and maleic acid have been investigated.

The DSC curves of these co-crystals show that their first endothermic peaks are all lower than the melting temperature of theophylline. The decomposition temperature of theophylline – oxalic acid co-crystal is at about 230 °C, determined by DSC together with TGA. After decomposition, the remaining theophylline melts at about 279 °C, which is higher than the known melting temperature of theophylline, suggesting a structure difference, ie. a new polymorph may have been formed. The formation of hydrogen bonds in theophylline – oxalic acid co-crystal was investigated by FTIR. Changes of FTIR peaks around 3120 cm^-1 reflects the hydrogen bond of basic N of theophylline and hydroxyl H of oxalic acid. The solubility of theophylline – oxalic acid co-crystal and theophylline – glutaric acid co-crystal was determined in 4:1 chlroform – methanol and in pure chloroform respectively. At equilibrium with the solid theophylline – oxalic acid co-crystal, the theophylline concentration is only 60 % of the corresponding value for the pure solid theophylline. At equilibrium with the solid theophylline – glutaric acid co-crystal, the theophylline concentration is at least 5 times higher than the corresponding value for the pure solid theophylline. Two phases of theophylline were found during the solubility determination. In the chloroform – methanol mixture (4:1 in volume ratio) the solubility of the stable polymorph of theophylline is found to be about 14 % lower than that of the metastable phase. Various aspects of the phase diagram of theophylline – oxalic acid co-crystal was explored.

Theophylline – oxalic acid co-crystal has been successfully prepared via primary nucleation from a stoichiometric solution mixture of the two components in chloroform – methanol mixture. By slurry conversion crystallization, the co-crystal can be prepared in several solvents, and yield and productivity can be significantly increased. Theophylline – glutaric acid can be successfully prepared via both co-grinding of the two components and slow evaporation with seeding.

QC20100608

5

Chrystyn, H. "Pharmacodynamics of theophylline in irreversible chronic airflow obstruction." Thesis, University of Bradford, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.379859.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Chen, Chi. "Engineering of inhalation aerosols combining theophylline and budesonide." Thesis, University of Bradford, 2014. http://hdl.handle.net/10454/14072.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

In asthma therapy, the use of theophylline to prevent bronchial spasm and glucocorticoids to decrease inflammation is widely indicated. Apart from the acute asthma attack oral theophylline is treated for chronic therapy in order to minimize inflammation and to enhance the efficiency of corticosteroids and recover steroids’ anti-inflammatory actions in COPD treatment. The preferred application route for respiratory disease treatment is by inhalation, such as dry powder inhalers (DPI) being the delivery systems of first choice. As shown recently, there is an advantageous effect if the drugs are given simultaneously which is caused by a synergistic effect at the same target cell in the lung epithelia. Therefore, it seems rational to combine both substances in one particle. This type of particle has the advantage over a combination product containing both drugs in a physical mixture which occurs rather randomly deposition leading to API segregation and non-dose-uniformity. Dry powder inhalers (DPIs) is a type of therapeutic pharmaceutical formulations usually present in the solid form. Due to the nature of the solid-state, an understanding of chemical and physical properties must be established for acquiring optimum performance of the active pharmaceutical ingredients (APIs). In recent year, generation of DPIs is a destructive procedure to meet the micron size. Such processes are inefficient and difficult to control. Moreover, according to current researches on combination APIs formulation, this type of DPIs performed a greater variability in does delivery of each active, leading to poor bioavailability and limit clinical efficient. This result suggest that combination formulations require advanced quality and functionality of particles with suitable physicochemical properties. Hence, in order to production of binary and combination DPIs products, the aim of this study was to develop the spray drying and ultrasonic process for engineering of combination drug particles that will be delivered more efficiently and independently of dose variations to the lung. Microparticles were produced by spray drying or/and ultrasonic technique. The processing parameters and addition of excipients (polymers) were optimized using a full factorial design such that microparticles were produced in a narrow size range suitable for inhalation. Employing excipients resulted in high saturation environment leading to minimized sphere particles when compared to conventional solvent. Solid state characterization of microparticles using powder x-ray diffraction and differential scanning calorimetry indicated that the particles contained crystalline but no cocrystal. The combination particles comparable to or better than micronized drug when formulated as a powder blended with lactose. It was concluded that the use of HPMC enhanced crystallinity suitable for inhalation; and combination particles improved uniform distribution on the stage of NGI.

7

Babey, Anna Marie. "Characterization of the time course of the effects of theophylline administration on adenosine receptors in cultured murine neuroblastoma cells." Thesis, McGill University, 1994. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=28668.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This thesis examines the effects of continuous theophylline pretreatment on the A$ sb2$ adenosine receptor system in cultured murine neuroblastoma cell lines, which either do or do not also express A$ sb1$ adenosine receptors. N-Ethylcarboxamido adenosine (NECA) stimulates cAMP accumulation and binds to A$ sb2$ receptors in a saturable and biphasic fashion in both types of cell cultures. Sixteen hours of theophylline treatment led to a significant increase in the number of low affinity A$ sb2$ binding sites, as well as a potentiation of NECA-stimulated cAMP accumulation, regardless of whether the cells expressed A$ sb1$ receptors. The enhanced adenylate cyclase stimulation in cells treated for 8 hours is completely blocked by addition of cycloheximide, indicating that new protein synthesis plays a role in the effects of theophylline. The potentiated response to NECA continues through 1 week of treatment in both sets of cultured cells, but disappears after 2 weeks of theophylline pretreatment in the cells expressing both A$ sb1$ and A$ sb2$ receptors. Binding profiles in cells that do not express A$ sb1$ receptors demonstrate that while control cells are sensitive to the effects of the non-hydrolyzable analogue of guanosine triphosphate, Gpp(NH)p, cells that were treated for 4 days or 1 week with theophylline are no longer sensitive to the effects of this compound. This could indicate either an enhanced coupling between the receptor and the stimulatory guanine nucleotide regulatory protein (G$ rm sb{s}$ protein) or a complete uncoupling of these two proteins. There is a significant decrease in the basal cAMP levels after 4 days or more of treatment, as well as an increase in the immunoreactivity of the $ alpha$ subunit of the stimulatory G protein after 2 weeks of treatment. Taken together, these findings would tend to favour the possibility of enhanced coupling between the receptor and the G$ rm sb{s}$ protein. Cells that express both receptor subtypes also show

8

LABOULAYE, PHILIPPE. "Les intoxications a la theophylline : indications therapeutiques a propos de trois observations." Amiens, 1989. http://www.theses.fr/1989AMIEM017.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Haarberg, Hans Eirik. "Theophylline IMAGEtags (intracellular multi aptamer genetic tags) the development and evaluation of an RNA reporter system based on the theophylline aptamer /." [Ames, Iowa : Iowa State University], 2009. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:1464205.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

JOSROLLAND, MONIQUE. "Les dosages de la theophylline dans les milieux biologiques." Strasbourg 1, 1987. http://www.theses.fr/1987STR10728.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Theophylline":

1

Maes, R. A. A. Theophylline profile. Weinheim, F.R.G: VCH, 1985.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

A, Maes Robert A., Oellerich Michael, and Enders Peter W, eds. Theophylline profile. Weinheim: VCH, 1985.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Friedrich, Kummer, ed. Asthma: Structural body-Theophylline today = strukturelle Grundlagen--Theophyllin heute. New York: Springer-Verlag, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Hughes, Angela. A theophylline compliance study. Ottawa: Ottawa Civic Hospital, 1990.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Jackson, Stephen Hugh David. Clinical aspects of theophylline pharmacokinetics. Birmingham: University of Birmingham, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Purkiss, Ronald. Bioequivalence of sustained release theophylline formulations. Birmingham: Aston University. Department of Pharmaceutical Sciences, 1986.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Bowen, James Marshall. Theophylline biotransformation by human lung microsomes. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Minton, Neil Andrew. The clinical pharmacology and toxicology of theophylline. Birmingham: University of Birmingham, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Shilalukey, Kathleen. Are current pediatric dose recommendations for intravenous theophylline appropriate? Ottawa: National Library of Canada, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

He, Juan. Theophylline 7-[beta]-D ribofuranoside production in mammalian tissues. Ottawa: National Library of Canada, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Theophylline":

1

Al-Qadheeb, Nada S. "Theophylline." In Textbook of Clinical Pediatrics, 2643–45. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_281.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Bährle-Rapp, Marina. "Theophylline." In Springer Lexikon Kosmetik und Körperpflege, 553. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-71095-0_10485.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Wilson, John Fawcett. "Theophylline." In The Immunoassay Kit Directory, 1613–25. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0679-5_49.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Prentice, Bernadette, Adam Jaffe, and Paul S. Thomas. "Theophylline." In Compendium of Inflammatory Diseases, 1252–54. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_53.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Ellis, Elliot F. "Theophylline." In Allergic Diseases, 345–60. Totowa, NJ: Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-007-0_19.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Gong, Li-Li, Li-Da Du, and Guan-Hua Du. "Theophylline." In Natural Small Molecule Drugs from Plants, 469–74. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8022-7_78.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Arampatzis, Adamantios, Lida Mademli, Thomas Reilly, Mike I. Lambert, Laurent Bosquet, Jean-Paul Richalet, Thierry Busso, et al. "Theophylline." In Encyclopedia of Exercise Medicine in Health and Disease, 849. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_3117.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Barnes, Peter J. "Theophylline." In Current Review of Asthma, 173–84. London: Current Medicine Group, 2003. http://dx.doi.org/10.1007/978-1-4613-1095-2_17.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Prentice, Bernadette, Adam Jaffe, and Paul S. Thomas. "Theophylline." In Encyclopedia of Inflammatory Diseases, 1–4. Basel: Springer Basel, 2014. http://dx.doi.org/10.1007/978-3-0348-0620-6_53-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Bährle-Rapp, Marina. "Methylsilanol Carboxymethyl Theophylline." In Springer Lexikon Kosmetik und Körperpflege, 354. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-71095-0_6559.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Theophylline":

1

Nag, Shreya, Debangana Das, Hemanta Naskar, Runu Banerjee Roy, Bipan Tudu, and Rajib Bandyopadhyay. "Estimation of Theophylline in Black Tea Using NIR Spectroscopy." In 2020 International Conference on Emerging Frontiers in Electrical and Electronic Technologies (ICEFEET). IEEE, 2020. http://dx.doi.org/10.1109/icefeet49149.2020.9186994.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Mędza, Grzegorz, Jacek Wierzchowski, and David Shugar. "Fluorescent analogues of caffeine, theophylline, and other methyl-xanthines." In XIVth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2008. http://dx.doi.org/10.1135/css200810478.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Jenkins, C. R., F. Q. Wen, P. J. Barnes, B. R. Celli, N. S. Zhong, J. P. Zheng, A. Martin, and N. Berend. "Theophylline and Systemic Corticosteroids in COPD: The TASCS Trial." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7444.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Almagro, Juan. "Hiperuricemic Impact Of Theophylline In A Long-term Administration." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1341.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Koniuch, Natalia. "Using transmission electron microscopy to monitor hydration of theophylline." In Microscience Microscopy Congress 2021 incorporating EMAG 2021. Royal Microscopical Society, 2021. http://dx.doi.org/10.22443/rms.mmc2021.255.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Feng, Zhanqin, Xueping Huang, Zengjuan Zheng, Wei Zhang, Shengjian Tang, and Weifen Zhang. "The characteristics of theophylline/chitosan microspheres as pulmonary delivery carriers." In International Conference on Medical Engineering and Bioinformatics. Southampton, UK: WIT Press, 2014. http://dx.doi.org/10.2495/meb140631.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Braga, Guilherme S., Leonardo G. Paterno, Fernando J. Fonseca, Manel del Valle, and Perena Gouma. "Molecularly Imprinted Polymer Based Sensor for the Detection of Theophylline." In OLFACTION AND ELECTRONIC NOSE: PROCEEDINGS OF THE 14TH INTERNATIONAL SYMPOSIUM ON OLFACTION AND ELECTRONIC NOSE. AIP, 2011. http://dx.doi.org/10.1063/1.3651655.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Singh, Mrityunjaya, Sudhir Kumar Agarwal, Manoj Meena, and Shruti Singh. "Effect of low dose theophylline as adjunct in treatment of COPD." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa303.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Cooney, Lewis, Daniel Hawcutt, and Ian Sinha. "Intravenous theophylline levels in children with acute asthma: A systematic review." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa314.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Dubuis, Eric, Mark A. Birrell, Michael Wortley, and Maria G. Belvisi. "Theophylline And Theobromine Block Excitation Of Sensory Nerves And Prevent Cough." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5544.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Theophylline":

1

Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations. National Institute for Health Research, January 2019. http://dx.doi.org/10.3310/signal-000708.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.